Novartis UK becomes a principal partner of the Royal College of Physicians
This month, Novartis UK has become a principal partner of the Royal College of Physicians (RCP). The partnership aspires to foster an exchange of information and resources and provides Novartis with the opportunity to work alongside the RCP to continue their mission to improve the standards of healthcare in the UK through advocacy, education and research.
The COVID-19 pandemic has caused a deep structural shift across the UK health and care system, which has catalysed new initiatives beyond traditional NHS collaborations. This partnership with the RCP aims to share insights in our work and best practices to ultimately drive innovation and improve healthcare for all patients.
The future delivery of healthcare should be focused on the needs of the population rather than the needs of individual institutions, which requires significant changes to current healthcare planning models. At Novartis, we have been taking steps to support the NHS and wider health and care systems in the UK to provide enhanced support in a post-COVID era.
As part of our goal to build a healthier tomorrow, we have reimagined our priorities by evaluating our existing products for the potential treatment of COVID-19 and its associated complications. We have also initiated a Health Hub Accelerator programme to support health tech start-ups providing solutions to challenges for the NHS created by COVID-19.
The RCP considers its partners as valued contributors to the development of the membership body of the RCP and, in addition to shared thought leadership, we will be looking to work with them on health improvement, medical education and global outreach.
Rosalind Way, Head of Strategic Partnerships at Novartis UK, said, “This exciting and transformative partnership with the Royal College of Physicians provides a great opportunity to make a positive impact on improving health and healthcare standards in the UK. We look forward to sharing key insights and learnings from Novartis and collaborating on projects to help solve challenges faced within the health and care system.”
Ian Bullock, Royal College of Physicians CEO, commented, “The RCP are delighted to be working in partnership with Novartis. The RCP corporate partnership programme is an opportunity for corporate stakeholders within the health sector to work alongside the RCP in sharing information, best practice and forward-thinking ideas.
The RCP corporate partnership programme aims to show the merits of collaboration and joint working in an increasingly challenging external environment of cost and resource pressures. We look forward to working with Novartis.”
About the Royal College of Physicians
The RCP is an independent, patient-centred, and clinically led organisation with 38,000 members in the UK and across the globe. It drives improvement in the diagnosis of disease, the care of individual patients and the health of the whole population. The RCP develops guidelines on behalf of NICE, sets standards in key areas of care, and measures that care through clinical audits and accreditation schemes. The oldest royal college in England, the RCP also works with policy makers, other royal colleges and other health organisations to embed quality improvement.
October 2020 | COR20-E106